sellWeak cluster of 2
Leslie Tari sold $39k of CDTX
CHIEF SCIENTIFIC OFFICER at Cidara Therapeutics, Inc.. 1,773 shares at an average of $21.96, traded Mar 11, 2025, filed Mar 13, 2025.
Warning score
29Value
$39k
1,773 shares
Holdings after
16,215
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +6Trade size$39k at market
- 0Share of holdings soldSold 9.9% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001610618-25-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | SOpen-market sale Common Stock | -1,773 | $21.96 | $39k | 16,215 | Mar 13, 2025 |
Related signals
Other insiders at Cidara Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | CDTXbuy Cidara Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $100M 2,272,727 shares | +208% | |
| 31Weak | CDTXbuy Cidara Therapeutics, Inc. | Chrysa Mineo director | $74k 3,320 shares | - | |
| 39Weak | Cidara Therapeutics, Inc. | Shane Ward COO & CLO | $37k 1,664 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.